Trial Profile
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 27 Sep 2021 Status changed from active, no longer recruiting to completed.
- 27 Jul 2021 Planned End Date changed from 1 Aug 2021 to 31 Aug 2021.
- 26 Mar 2021 Planned End Date changed from 31 Jan 2021 to 1 Aug 2021.